Trial Profile
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs AGS 67E (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Agensys; Astellas Pharma Global Development
- 20 Nov 2018 Status changed from suspended to discontinued due to business decision by sponsor
- 30 Nov 2017 Status changed from recruiting to suspended.
- 02 May 2017 Planned End Date changed from 1 Nov 2017 to 11 Sep 2018.